2026 article

Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL

Hrishikesh K. Srinagesh, Vishal Gupta, Amy Zhang, Michael R Grunwald, Matthew P Connor, Vamsi Kota, Jacob Boccucci, M. Ulrickson, Roshini Pradeep, L Hill, Stephanie B. Tsai, TIMOTHY E. O'CONNOR, Karamjeet Sandhu, Anjali S. Advani, Ran Reshef, Christian Gordillo, Marlise R. Luskin, Evan C. Chen, Chenyu Lin, Ryan D. Cassaday, Noam E. Kopmar, Navneet S. Majhail, Minoo Battiwalla, Stephen A. Strickland, C F Lee, Silvina Odstrcil Bobillo, Talal Hilal, Jae H Park, Yannis K. Valtis, Rawan Faramand, Melhem M Solh, Caitlin Guzowski, Sumithira Vasu, Jessica Leonard, Virginia Tan, Eunice S. Wang, Ross McCauley, Joshua Sasine, Kevin Tang, Miller Kk, Katherine C. Sutherland, Michael Daunov, Razan Mohty, Omer Jamy, Muthu Sendhil Kumaran, Rasmus T. Hoeg, Kaitlyn C. Dykes, Aaron Logan, Tamer Othman, Wendy A Stock, Marc S. Schwartz, Kenneth Byrd, Fevzi Yalniz, Veronika Bachanova, Sean Tracy, George Yaghmour, Vivian Irizarry Gatell, Clayton Jackson, Olalekan O. Oluwole, Bhagirathbhai Dholaria, Kristen M O'Dwyer, Jozal Moore, Gregory W. Roloff, Noelle V. Frey, Ibrahim Aldoss, B. D. Shah, Caspian Oliai, Lori Muffly

3Citations signalées — pas une note de qualité

49Institutions déclarées

2Pays d’affiliation déclarés

Résumé fourni par la source

ABSTRACT: In a real-world analysis of brexucabtagene autoleucel recipients with relapsed/refractory B-cell acute lymphoblastic leukemia (N = 278), lack of response to prior blinatumomab correlates with significantly worse following chimeric antigen receptor T-cell therapy outcomes.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref: Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL
Date Crossref: 23/04/2026
Éditeur: American Society of Hematology
Type: journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.

Institutions déclarées

Palo Alto University Stanford Medicine Stanford University University of California, Los Angeles University of California System Levine Cancer Institute Hospital of the University of Pennsylvania Augusta University Augusta University Health The University of Texas MD Anderson Cancer Center Baylor College of Medicine Loyola University Medical Center City of Hope Cleveland Clinic Columbia University Irving Medical Center Dana-Farber Cancer Institute Duke University University of Washington Fred Hutch Cancer Center Centennial Medical Center Huntsman Cancer Institute Mayo Clinic in Arizona Mayo Clinic Hospital Memorial Sloan Kettering Cancer Center Moffitt Cancer Center Northside Hospital The Ohio State University Oregon Health & Science University Roswell Park Comprehensive Cancer Center Cedars-Sinai Medical Center Stanford Blood Center University Hospitals Seidman Cancer Center University of Alabama at Birmingham University of Arkansas Medical Center University of Arkansas for Medical Sciences University of California, Davis University of California San Diego University of California, San Francisco University of Chicago University of Colorado Anschutz University of Colorado Denver Cellular Therapeutics (United Kingdom)University of Kentucky University of Minnesota University of Southern California USC Norris Comprehensive Cancer Center The University of Texas Southwestern Medical Center Vanderbilt University Medical Center University of Rochester

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Sujets associés

CAR-T cell therapy researchAcute Lymphoblastic Leukemia researchChronic Myeloid Leukemia Treatments

Consulter la publication primaire DOI